AVOID CONCOMITANT USE OF STRONG CYP3A4 INHIBITORS (E.G., KETOCONAZOLE, ITRACONAZOLE, CLARITHROMYCIN, ATAZANAVIR, NEFAZODONE, SAQUINAVIR, TELITHROMYCIN, RITONAVIR, INDINAVIR, NELFINAVIR, VORICONAZOLE). FOR PATIENTS WHO REQUIRE TREATMENT WITH A STRONG CYP3A4 INHIBITOR, REDUCE THE DAILY CABOZANTINIB DOSE BY 40 MG.
AVOID THE CHRONIC USE OF CONCOMITANT STRONG CYP3A4 INDUCERS (E.G., PHENYTOIN, CARBAMAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, PHENOBARBITAL, ST. JOHN'S WORT. INCREASE THE DAILY CABOZANTINIB DOSE BY 40 MG IF THESE SALTS ARE ATALL TO BE USED.